Real World Evidence Solutions

Global Real World Evidence Solutions Market to Reach US$4.4 Billion by 2030

The global market for Real World Evidence Solutions estimated at US$1.9 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 14.4% over the analysis period 2024-2030. Services, one of the segments analyzed in the report, is expected to record a 15.6% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Data Sets segment is estimated at 12.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$534.3 Million While China is Forecast to Grow at 13.3% CAGR

The Real World Evidence Solutions market in the U.S. is estimated at US$534.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$652.6 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.

Global Real World Evidence Solutions Market - Key Trends and Drivers Summarized

Real World Evidence Solutions: Transforming Healthcare with Data-Driven Insights

Real World Evidence (RWE) solutions are transforming healthcare by providing data-driven insights that enhance decision-making across the industry. RWE refers to the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD). This data is collected from various sources, including electronic health records (EHRs), claims databases, patient registries, and wearable devices. RWE is increasingly being used by pharmaceutical companies, regulators, and healthcare providers to inform drug development, regulatory approvals, and patient care strategies. Unlike traditional clinical trials, which are conducted under controlled conditions, RWE provides insights into how treatments perform in everyday clinical settings, offering a more comprehensive understanding of a product’s effectiveness and safety. This approach is becoming essential for demonstrating the value of new therapies, especially in personalized medicine and for rare diseases.

What Technological Advancements Are Enhancing the Collection and Utilization of RWE?

Technological advancements are significantly enhancing the collection, analysis, and utilization of RWE, making it a more powerful tool for healthcare stakeholders. The integration of big data analytics, artificial intelligence (AI), and machine learning (ML) into RWE platforms allows for the processing of vast amounts of RWD, uncovering patterns and insights that would be impossible to detect manually. Advances in data integration technologies are also enabling the aggregation of data from diverse sources, creating comprehensive datasets that provide a holistic view of patient outcomes. Moreover, the use of natural language processing (NLP) is improving the extraction of meaningful data from unstructured sources, such as physician notes and social media. These technological innovations are not only improving the quality and accuracy of RWE but are also making it more accessible and actionable for decision-makers in healthcare.

What Are the Key Applications and Benefits of RWE in Healthcare?

RWE is used in a wide range of applications in healthcare, offering significant benefits that enhance patient outcomes, improve healthcare efficiency, and support regulatory decision-making. In drug development, RWE is used to supplement clinical trial data, providing insights into how a drug performs across different populations and in real-world settings, which can inform labeling and post-market surveillance. Healthcare providers use RWE to identify the most effective treatments for specific patient populations, supporting personalized medicine approaches that tailor care to individual needs. Payers and insurers leverage RWE to assess the cost-effectiveness of treatments, guiding reimbursement decisions and ensuring that resources are allocated to therapies that offer the greatest value. The primary benefits of RWE include its ability to provide insights into the real-world effectiveness and safety of medical products, support evidence-based decision-making, and improve patient care by informing treatment strategies based on actual patient experiences.

What Factors Are Driving the Growth in the Real World Evidence Solutions Market?

The growth in the Real World Evidence Solutions market is driven by several factors. The increasing emphasis on value-based care and the need to demonstrate the real-world effectiveness of medical products are significant drivers, as healthcare stakeholders seek to make informed decisions based on robust evidence. Technological advancements in data analytics, AI, and digital health platforms are also propelling market growth by enhancing the capabilities and accessibility of RWE solutions. The rising demand for personalized medicine and the need for data to support regulatory approvals, particularly for rare diseases and complex conditions, are further boosting demand for RWE. Additionally, the growing availability of digital health data, driven by the adoption of EHRs, wearable devices, and patient-reported outcomes, is expanding the scope and scale of RWE studies. These factors, combined with increasing collaboration between pharmaceutical companies, healthcare providers, and regulatory bodies, are driving the sustained growth of the Real World Evidence Solutions market.

SCOPE OF STUDY:

The report analyzes the Real World Evidence Solutions market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Services, Data Sets); End-Use (Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

• Aetion
• Cognizant Technology Solutions U.S. Corporation
• IBM Corporation
• Ignite Data Limited
• IQVIA
• PAREXEL International Corporation
• PerkinElmer, Inc.
• Pharmaceutical Product Development LLC
• SAS Institute, Inc.
• Syneos Health

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.